Prospera Private Wealth LLC Takes Position in Celcuity Inc. (NASDAQ:CELC)

Prospera Private Wealth LLC acquired a new position in shares of Celcuity Inc. (NASDAQ:CELC) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,350 shares of the company’s stock, valued at approximately $35,000.

Other institutional investors have also recently modified their holdings of the company. nVerses Capital LLC purchased a new position in Celcuity during the third quarter worth $33,000. Values First Advisors Inc. purchased a new stake in Celcuity during the 3rd quarter worth about $86,000. Quest Partners LLC raised its stake in Celcuity by 31.3% in the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after purchasing an additional 1,379 shares during the last quarter. SG Americas Securities LLC purchased a new position in Celcuity in the 3rd quarter valued at about $119,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Celcuity by 78.5% during the 1st quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock worth $193,000 after purchasing an additional 3,930 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Price Performance

Shares of Celcuity stock opened at $13.19 on Friday. The business’s fifty day moving average price is $14.93 and its 200 day moving average price is $15.92. Celcuity Inc. has a twelve month low of $11.51 and a twelve month high of $22.19. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $489.74 million, a P/E ratio of -4.89 and a beta of 0.76.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Stifel Nicolaus upped their price objective on shares of Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, October 7th. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Celcuity in a research note on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Celcuity in a research report on Friday, November 15th. Finally, Lifesci Capital assumed coverage on Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Celcuity currently has a consensus rating of “Buy” and an average price target of $29.17.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.